药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Aluminium monostearate
Phenyl aminosalicylate
The therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Dexibuprofen.
Aluminium monostearate
Dersalazine
The therapeutic efficacy of Dersalazine can be decreased when used in combination with Dexibuprofen.
Aluminium monostearate
Desvenlafaxine
The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Dexibuprofen.
Aluminium monostearate
Milnacipran
The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Dexibuprofen.
Aluminium monostearate
Alaproclate
The risk or severity of gastrointestinal bleeding can be increased when Alaproclate is combined with Dexibuprofen.
Aluminium monostearate
Ritanserin
The risk or severity of gastrointestinal bleeding can be increased when Ritanserin is combined with Dexibuprofen.
Aluminium monostearate
Indalpine
The risk or severity of gastrointestinal bleeding can be increased when Indalpine is combined with Dexibuprofen.
Aluminium monostearate
Seproxetine
The risk or severity of gastrointestinal bleeding can be increased when Seproxetine is combined with Dexibuprofen.
Aluminium monostearate
Dapoxetine
The risk or severity of gastrointestinal bleeding can be increased when Dapoxetine is combined with Dexibuprofen.
Aluminium monostearate
Hygromycin B
The risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Hygromycin B.
Aluminium monostearate
Dihydrostreptomycin
The risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Dihydrostreptomycin.
Aluminium monostearate
Puromycin
The risk or severity of nephrotoxicity can be increased when Puromycin is combined with Dexibuprofen.
Aluminium monostearate
Neamine
The risk or severity of nephrotoxicity can be increased when Neamine is combined with Dexibuprofen.
Aluminium monostearate
Apramycin
The risk or severity of nephrotoxicity can be increased when Apramycin is combined with Dexibuprofen.
Aluminium monostearate
Geneticin
The risk or severity of nephrotoxicity can be increased when Geneticin is combined with Dexibuprofen.
Aluminium monostearate
Paromomycin
The risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Dexibuprofen.
Aluminium monostearate
Givosiran
The risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Givosiran.
Aluminium monostearate
Phenazopyridine
The risk or severity of nephrotoxicity can be increased when Phenazopyridine is combined with Dexibuprofen.
Aluminium monostearate
Inotersen
The risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Inotersen.
Aluminium monostearate
Adefovir
The risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Adefovir.